Supplementary Table 1 from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1. Toxicities; Supplementary Table 2. Patient characteristics and response evaluation; Supplementary Table 3. Patient Correlative Study Results
Authors: Elizabeth L. McMichael, Brooke Benner, Lakhvir S. Atwal, Nicholas B. Courtney, Xiaokui Mo, Melanie E. Davis, Amanda R. Campbell, Megan C. Duggan, Kallan Williams, Kyle Martin, Kala Levine, Gonzalo N. Olaverria Salavaggione, Tiffany Noel, Akaansha Ganju, Sarvani Uppati, Bonnie Paul, Thomas Olencki, Theodoros N. Teknos, Panos Savvides, Susheela Tridandapani, John C. Byrd, Michael A. Caligiuri, Stephen V. Liu, William E. Carson
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361888061